p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis - Wikidata - wikimedia - TriplyDB

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

http://www.wikidata.org/entity/Q34848523

about

Alterations of the TP53 gene in gastric and esophageal carcinogenesis Prognostic factors for esophageal squamous cell carcinoma--a population-based study in Golestan Province, Iran, a high incidence area.Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus.Rapid detection of SNP (c.309T>G) in the MDM2 gene by the Duplex SmartAmp method.Genetic variants in epidermal growth factor receptor pathway genes and risk of esophageal squamous cell carcinoma and gastric cancer in a Chinese population.A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.Association between positive murine double minute 2 expression and clinicopathological characteristics of esophageal squamous cell carcinoma: a meta-analysis.Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma.The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan.Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer p Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.Impact of pre-diagnosis behavior on risk of death from esophageal cancer: a systematic review and meta-analysis.Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer.Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model.DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.Correlations of ALDH2 rs671 and C12orf30 rs4767364 polymorphisms with increased risk and prognosis of esophageal squamous cell carcinoma in the Kazak and Han populations in Xinjiang province.Genetic variants in CHEK1 gene are associated with the prognosis of thoracic esophageal squamous cell carcinoma patients treated with radical resection.The p53 R72P polymorphism does not affect the physiological response to ionizing radiation in a mouse model.A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

P2860

Q26866191-7ECA8115-78FA-4E2A-AFF1-CDB0BE1C6F52 Q33979719-D7B55F41-0704-4AF3-9B80-2C6E718764D4 Q34500998-1429FDA1-1BFC-4DA6-9515-10A56D766545 Q34658158-EF12D0A6-4399-4150-B4FB-121048EBA7BD Q34852402-92C4526B-9CE1-4207-A539-3B9DFC81F5F1 Q35218636-3170BF93-2493-45C5-B291-28D03B5D0EFE Q35601228-E261DC56-D72D-42B7-9159-1582BB1CB101 Q35609733-DD1FF507-5A14-4C9A-B55E-CC42A23898FB Q36810210-F06089F0-84F6-4F2A-BB2F-332EEA1393F7 Q36923010-E14BB905-322F-497D-9F23-1AE06B6EEA80 Q37580616-79C94C11-2848-4021-8CF7-AA74B4D2D156 Q37648073-FB244B43-8850-4579-AFFF-56E2B25A25C3 Q38554255-6BA9916B-E278-4AE8-88AF-B2F0C853A7B6 Q38834922-C2E6FA27-E0DD-4AA9-A7E4-8213562D194C Q42138668-C0B3D70D-B9F7-4469-8D67-7E1BA6994739 Q42749109-869C4158-873F-46EA-9CA9-30F5B7AC92A3 Q44000617-A7F6EF6B-5634-4BE3-BE43-0A39417FB6FF Q45228677-1D1E756E-5A95-41C7-8EE4-BEDF06DBB68C Q48206628-42C02B3A-9D06-4716-B7AC-3BF91CA1725F Q51281982-B9433DF3-70BD-4874-AE9A-7B54DFE1A79A Q52766257-7FEF04F9-0A67-472B-B236-F165EAF79834 Q58763391-00384BFC-7F7E-481B-8EC7-9AADF5308D96

P2860

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

http://www.wikidata.org/entity/Q34848523

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@ast

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@en

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@nl

type

label

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@ast

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@en

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@nl

prefLabel

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@ast

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@en

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@nl

P1433

Q34848523-DD0F5BD8-E001-403A-BD1B-502CB9C391AB

P1476

Q34848523-C3B711F0-916A-4FA6-8A7E-70E664037033

P2093

Q34848523-249C659C-48D8-476F-8672-7E5CBDA9B548

Q34848523-26861D6A-4556-4393-BB8F-05869109A7B9

Q34848523-3AD1A2AD-9D76-447F-9624-493B2810E7DE

Q34848523-4BB19A81-C989-46E6-9723-049CD3D58469

Q34848523-50799D32-D722-45F3-BC85-243D17009917

Q34848523-54B88710-B988-46E5-901D-598143AF2206

Q34848523-55475E78-01F2-4DA1-80CE-6A6F57234B9C

Q34848523-65C0F0A2-7567-4B97-BEC6-322CA73B65DD

Q34848523-6B582480-2A8D-40B2-A006-F93B168AFA67

Q34848523-90253550-6E3B-453A-B588-BABC9B7769EF

P2860

Q34848523-04DB41B0-FF85-48C5-9E61-B6B0C1F6015A

Q34848523-0550BC47-ED0E-4198-B837-2CAB19015262

Q34848523-0AA96327-5666-4AAD-8AFA-44355F4DB331

Q34848523-0F584EEC-19DA-47D5-9AAB-D3E04B91956F

Q34848523-196DF893-B084-4D84-9B57-3F2451512548

Q34848523-1DC1EDB7-DFCA-4A4A-9A16-34C2C317CB1E

Q34848523-25D05BE8-25F8-48BB-9A4B-47D5C413C109

Q34848523-2760FC24-E7A3-4244-AC1F-A0AFC7E4C370

Q34848523-3369E9AA-1A14-4035-8D8C-33439EA017D7

Q34848523-33E1FA36-D8B8-46B8-9141-F7DAC35A496B

P304

Q34848523-DAE7F787-31B2-4058-81C9-E1FAB2483393

P31

Q34848523-5AF5F762-F697-4C8D-B368-D626C912F3D2

P356

Q34848523-9E2ABBB0-A6F5-41EF-A676-A6A7DB6ED0DB

P407

Q34848523-1FA1CC5E-42C3-4E1A-8B90-4011910701D7

P433

Q34848523-74DA078E-0403-41BB-B181-42EBC8C89676

P478

Q34848523-041F5596-3EC3-4DDA-BC01-7AF5BEB2FE8F

P50

Q34848523-C87AF8DE-444E-40EC-A10E-2C4D2129D3A7

P577

Q34848523-BEED5B1E-A497-4DF3-8064-91E8B1212B05

P698

Q34848523-8B64997D-2B88-44FB-81EF-148A54998AC8

P932

Q34848523-9C339F89-EEE6-4131-9DF4-86DCCD786344

P356

1078-0432.CCR-08-3120

P1433

Clinical Cancer Research

P1476

p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis

@en

P2093

Ariela L Marshall

http://www.w3.org/2001/XMLSchema#string

Clement Ma

http://www.w3.org/2001/XMLSchema#string

David C Christiani

http://www.w3.org/2001/XMLSchema#string

David W Cescon

http://www.w3.org/2001/XMLSchema#string

Jessica Hopkins

http://www.w3.org/2001/XMLSchema#string

John C Wain

http://www.w3.org/2001/XMLSchema#string

Kofi Asomaning

http://www.w3.org/2001/XMLSchema#string

Li Su

http://www.w3.org/2001/XMLSchema#string

Matthew Kulke

http://www.w3.org/2001/XMLSchema#string

Penelope A Bradbury

http://www.w3.org/2001/XMLSchema#string

P2860

p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma

Molecular biology of upper gastrointestinal malignancies.

Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect.

Polymorphisms in the p53 pathway.

p53 and disease: when the guardian angel fails.

Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.

Are squamous and adenocarcinomas of the esophagus the same disease?

American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

P304

3103-3109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-3120

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19383811

http://www.w3.org/2001/XMLSchema#string

P932

3081782

http://www.w3.org/2001/XMLSchema#string